Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study

Inal, A.; Kos, F.; Algin, E.; Yildiz, R.; Berk, V.; Unek, I.; Colak, D.; Kucukoner, M.; Elkiran, E.; Helvaci, K.; Geredeli, C.; Dane, F.; Balakan, O.; Kaplan, M.; Durnali, A.; Harputoglu, H.; Goksel, G.; Ozdemir, N.; Buyukberber, S.; Gumus, M.; Ozkan, M.; Benekli, M.; Isikdogan, A.

Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study

Atıf İçin Kopyala

Inal A., Kos F. T., Algin E., Yildiz R., Berk V., Unek I. T., ...Daha Fazla

JOURNAL OF BUON, cilt.17, sa.1, ss.102-105, 2012 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 17 Sayı: 1
Basım Tarihi: 2012
Dergi Adı: JOURNAL OF BUON
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.102-105
Anahtar Kelimeler: cancer, gemcitabine, pancreas, prognosis, SINGLE-AGENT GEMCITABINE, RANDOMIZED PHASE-III, ADENOCARCINOMA, INDEX
Gazi Üniversitesi Adresli: Evet

Özet

Purpose: The majority of patients with pancreatic cancer present with advanced disease. Systemic chemotherapy for patients with pancreatic cancer has limited impact on overall survival (OS). Patients eligible for chemotherapy should be selected carefully. The aim of this study was to analyse prognostic factors for OS in advanced pancreatic cancer patients treated with first-line palliative chemotherapy with gemcitabine alone or gemcitabine plus cisplatin.